Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXTEND-03: Debio 4126 in Acromegaly
NCT06930625Phase 3Recruiting
- Sponsor
- Debiopharm
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Drug Delivery Systems
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of Debio 4126 in acromegaly (3 arms), sponsored by Debiopharm. Primary endpoint: Double-blind Period: Percentage of Participants With IGF-1 <=1x ULN at 36 weeks. Started Nov 2025; status: recruiting.
02
Drugs
Debio 4126
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT06930625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930625.